Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
According to our (Global Info Research) latest study, the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size was valued at US$ 5214 million in 2023 and is forecast to a readjusted size of USD 9941 million by 2030 with a CAGR of 9.8% during review period.
Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.
This report is a detailed and comprehensive analysis for global Liposomal and Lipid Nanoparticle Drug Delivery Systems market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size and forecasts, in consumption value ($ Million), 2019-2030
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Liposomal and Lipid Nanoparticle Drug Delivery Systems
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Liposomal and Lipid Nanoparticle Drug Delivery Systems market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Liposomal and Lipid Nanoparticle Drug Delivery Systems market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Market segment by Application
Hospital
Retail Pharmacy
Other
Market segment by players, this report covers
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Liposomal and Lipid Nanoparticle Drug Delivery Systems product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Liposomal and Lipid Nanoparticle Drug Delivery Systems, with revenue, gross margin, and global market share of Liposomal and Lipid Nanoparticle Drug Delivery Systems from 2019 to 2024.
Chapter 3, the Liposomal and Lipid Nanoparticle Drug Delivery Systems competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Liposomal and Lipid Nanoparticle Drug Delivery Systems market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Liposomal and Lipid Nanoparticle Drug Delivery Systems.
Chapter 13, to describe Liposomal and Lipid Nanoparticle Drug Delivery Systems research findings and conclusion.
Summary:
Get latest Market Research Reports on Liposomal and Lipid Nanoparticle Drug Delivery Systems. Industry analysis & Market Report on Liposomal and Lipid Nanoparticle Drug Delivery Systems is a syndicated market report, published as Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Liposomal and Lipid Nanoparticle Drug Delivery Systems market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.